Pentixapharm Holding AG Amends Convertible Bond Terms with Eckert & Ziegler SE

Pentixapharm Holding AG has reached an agreement with Eckert & Ziegler SE to extend the term of its 4.00% Corporate Convertible Bond from the end of 2027 to 2030. This arrangement increases the company's financial flexibility by allowing it to draw on the bond's remaining €13.5 million until mid-2030, while deferring the repayment of already issued bonds.

The amended terms result in an increase in the interest rate from 4.00% to 6.00% starting January 2027. Pentixapharm also gained the right to early redemption at the bond's principal value plus interest. Conversion rights can now be exercised at any time during the bond's extended duration.

Significant internal management changes accompany this amendment, with assurances for equitable security arrangements for other bonds. The company plans to propose a capital increase to accommodate the full conversion rights at the 2027 Annual General Meeting.